Recent submissions

Comment · 6 days ago
Are you questioning Mr. Alexander Hamilton's New York Post???
Comment · 1 month ago
Code deception 10% at 5.6 to 1.3% for 6.0? So models are getting more safe rather than less safe? hmmm
Comment · 2 years ago
This is one of the best, funniest pieces of writing I have read in months - The utter detachment and cynicism displayed around this borderline Hunter S Thompson acid trip is breath of fresh air.
Comment · 3 years ago
ML researchers would get a lot of interesting ideas from Ed Yong's book: "An Immense World: How Animal Senses Reveal the Hidden Realms Around Us"

It goes through the extraordinarily diverse sensory systems of all animals. In the push for at-the-edge, exteme-low-latency, low-resource "intelligent" agents, mimicking some of these system may lead to cool systems.

Comment · 4 years ago
Are the vertical-specific Nvidia SDKs like DRIVE and Clara widely used?
Comment · 4 years ago
Comment · 4 years ago
Does anyone have any experience in comparing Carta's comp and equity estimation tool to the reality? The cash seems aligned with what I see in the market but the equity always seems a little low
Comment · 4 years ago
Gil Strang got me through Lin alg, stopped going in person after I found his videos. Haven’t heard that name in years.
Comment · 4 years ago
FDA absolutely reviews stated design processes and audits against these. See 21CFR211 - The perspective here is that even if we are actually pretty confident that it is just "one little tweak here", a one-letter change could have wide ranging affects when interacting with the human body.
Comment · 4 years ago
I didn't say it was just marketing - I was asking for additional data to shed light on how robust (or frail) this result is. I don't think there is enough in this press release.

edit: (maybe you meant to comment on that other comment on this...)

Comment · 4 years ago
Is there a comprehensive white-paper anywhere with sample sizes and error bars? Otherwise this seems like an anecdote.

"The sera were collected from subjects 3 weeks after receiving the second dose or one month after receiving the third dose of the Pfizer-BioNTech COVID-19 vaccine"

How do we know this study isn't just measuring the effect of that additional week? Also how many subjects was this sera pulled from? Are the subjects materially similar between the second and third dose groups?

Not exactly surprising the people selling the third dose conclude that it is needed. It's like when the waiter recommends the most expensive option.

Comment · 5 years ago
Facebook generates this much free cash flow in 3 days.

This is irrelevant

Live from the official Hacker News API

A modern reader for Hacker News · SvelteKit + Skeleton